TouchRESPIRATORY got the opportunity to catch up with Dr Iwein Gyselinck around the DAWn-AZITHRO trial of azithromycin antiviral therapy for patients with COVID-19.
The abstract ‘Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof of concept clinical trial.’ (Presentation ID 2666) was presented at ERS International Congress 2021, 5-8 September 2021.
Questions
- Why has the search for an effective direct acting antiviral for COVID-19 been so challenging? (0:19)
- How has the design of the DAWn-studies sought to overcome these challenges? (1:32)
- What is known about the potential of azithromycin as an antiviral therapy for patients with COVID-19? (2:43)
- What are the aims, methodology and inclusion criteria of the DAWn-AZITHRO study? (3:41)
- What is the primary outcome measure and what were the findings presented at ERS? (5:01)
Disclosures: Iwein Gyselinck has nothing to disclose in relation to this video.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ERS 2021 (Virtual).
